Nabumetone is a nonacidic NSAID that is rapidly metabolized in the liver to a major active metabolite, 6-methoxy-2-naphthyl acetic acid. As found with previous NSAIDs, nabumetone's active metabolite inhibits the cyclooxygenase enzyme and preferentially blocks COX-2 activity (which is indirectly responsible for the production of inflammation and pain during arthritis). The active metabolite of nabumetone is felt to be the compound primarily responsible for therapeutic effect. Comparatively, the parent drug is a poor inhibitor of COX-2 byproducts, particularly prostaglandins. It may be less nephrotoxic than indomethacin. There are two known polymorphs of the compound.
Nabumetone has little effect on renal prostaglandin secretion and less of an association with heart failure than other traditional drugs of the class. Effects of nabumetone on blood pressure control in hypertensive patients on ACE inhibitors is also good—equivalent to paracetamol. As of 2015 the cost for a typical month of medication in the United States is 25 to US$50.
Similar in action to other NSAIDs, Nabumetone is used to treat pain and inflammation.
It has been shown to have a slightly lower risk of gastrointestinal side effects than most other non-selective NSAIDs since it is a non-acidic prodrug which is then metabolized to its active 6MNA (6-methoxy-2-naphthylacetic acid) form.
Side effects include: Bloody or black, tarry stools; change in color, frequency, or amount of urine; chest pain; shortness of breath; coughing up blood; pale stools; numbness; weakness; flu-like symptoms; leg pain; vision problems; speech problems; problems walking; weight gain; stomach pain; shortness of breath; cold sweat; skin rash; blisters; headache; swelling; bleeding; bruising; vomiting blood; jaundice; diarrhea; constipation; dizziness; indigestion; gas; nausea; and ringing in the ears.
Assay of nabumetone
There are few papers published reporting analytical methods for nabumetone. Two of them employed HPLC with UV-detection. One HPLC method using direct injection on restricted access media columns. Flow injection analysis (FIA) with UV-detection was also reported for the determination of nabumetone in pharmaceutical preparations. Methods using HPLC with fluorescence detection  were reported. M. Nobilis et al. carried out biotransformation and disposition studies in humans and minipigs using HPLC with UV, fluorescence and mass spectrometric detection. The interactions with gamma-cyclodextrin were also studied by fluorescence measurements. Assay methods employed HPLC using UV detection, photodiode array (PDA) detector and mass spectrometric detection for the determination of nabumetone and its metabolites. Murillo Pulgarín et al. reported three analytical methods using different techniques along with phosphorescence. Liquid chromatography methods using different techniques of mass spectrometry were also reported. The electrochemical behavior of nabumetone by a voltammetric technique  and a novel colorimetric method based on chemical derivatization  were also published. P. K. Sahu et al. has reported a HPLC method for simultaneous estimation of nabumetone and paracetamol in combined dosage form.
^Gonzalo-Garijo MA, Cordobés-Duran C, Lamilla-Yerga AM, Moreno-Gastón I (2007). "Severe immediate reaction to nabumetone". Journal of Investigational Allergology and Clinical Immunology. 17 (4): 274–6. PMID17694703.
^Olsen, N V; Jensen, N G; Hansen, J M; Christensen, N J; Fogh-Andersen, N; Kanstrup, I L (1999). "Non-steroidal anti-inflammatory drugs and renal response to exercise: a comparison of indomethacin and nabumetone". Clinical Science. 97 (4): 457–465. doi:10.1042/cs0970457.
^Price, C P; Grzesiak, A L; Lang, M; Matzger, A J (2002). "Polymorphism of Nabumetone". Crystal Growth & Design. 2 (6): 501–503. doi:10.1021/cg0255568.
^Palmer, Robert H; Haig, Ann E; Flavin, Susan K; Iyengar, Malini K (2001). "Effects of ibuprofen (IB), nabumetone (N) and celecoxib (C) on blood pressure (BP) control in hypertensive patients on ACE inhibitors". American Journal of Hypertension. 14 (S1): 85A. doi:10.1016/S0895-7061(01)01811-8.
^Hamilton, Richart (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 9. ISBN9781284057560.
^ abSahu, Prafulla Kumar; Annapurna, M. Mathrusri (2009). "Analysis of Nabumetone in Bulk and Tablet Formulation by a New and Validated Reverse Phase High Performance Liquid Chromatography". e-Journal of Chemistry. 6(S1): S59–S64. ISSN0973-4945.
^Al-Momani Idrees, F (1997). "Determination of Nabumetone and Its Major Metabolite in Plasma and Tablet Formulations by Reverse-Phase HPLC". Analytical Letters. 1997 (30): 2485–2492. doi:10.1080/00032719708001759.
^Jang, E J; Lee, Y J; Park, M G; Shim, C K (1995). "HPLC Assay of 6-Methoxy-2-Naphthylacetic Acid, a Major Metabolite of Nabumetone, in Human Serum". Analytical Letters. 28 (13): 2379–2389. doi:10.1080/00032719508000379.
^Can, N O; Tuncel, M; Aboul-Enein, H Y (2003). "Determination of nabumetone in pharmaceutical formulation by flow injection analysis (FIA) with UV-detection". Die Pharmazie. 58 (1): 22–24. PMID12622247.
^Mikami, E; Goto, T; Ohno, T; Matsumoto, H; Nishida, M (2000). "Simultaneous analysis of naproxen, nabumetone and its major metabolite 6-methoxy-2-naphthylacetic acid in pharmaceuticals and human urine by high-performance liquid chromatography". Journal of Pharmaceutical and Biomedical Analysis. 23 (5): 917–925. doi:10.1016/s0731-7085(00)00365-4. PMID11022916.
^Kobylińska, Kamila; Barlińska, Małgorzata; Kobylińska, Maria (2003). "Analysis of nabumetone in human plasma by HPLC. Application to single dose pharmacokinetic studies". Journal of Pharmaceutical and Biomedical Analysis. 2003 (32): 323–328. doi:10.1016/S0731-7085(03)00078-5. PMID12763542.
^Nobilis, M; Kopecký, J; Kv, Tina J; Svoboda, Z; Pour, M; Kune, J; Hol, Apek M; Kolá, Ová L (2003). "Comparative biotransformation and disposition studies of nabumetone in humans and minipigs using high-performance liquid chromatography with ultraviolet, fluorescence and mass spectrometric detection". Journal of Pharmaceutical and Biomedical Analysis. 32 (4–5): 641–656. doi:10.1016/s0731-7085(03)00171-7. PMID12899954.
^Al-Rawashdeh, A F Nathir (2005). "Interactions of Nabumetone with γ-Cyclodextrin Studied by Fluorescence Measurements". Journal of Inclusion Phenomena and Macrocyclic Chemistry. 51 (1–2): 27–32. doi:10.1007/s10847-004-1502-9.
^Nageswara, Rao R; Meena, S; Nagaraju, D; Raghu Ram, Rao A (2004). "Development and validation of a reversed-phase liquid chromatographic method for separation and simultaneous determination of COX-2 inhibitors in pharmaceuticals and its application to biological fluids". Biomedical Chromatography. 19 (5): 362–368. doi:10.1002/bmc.458. PMID15627281.
^Nobilis, M; Holcapek, M; Kolárová, L; Kopecký, J; Kunes, M; Svoboda, Z; Kvetina, J (2004). "Identification and determination of phase II nabumetone metabolites by high-performance liquid chromatography with photodiode array and mass spectrometric detection". Journal of Chromatography A. 1031 (1–2): 229–236. doi:10.1016/j.chroma.2004.01.031. PMID15058587.
^Murillo, Pulgarín J A; Alañón, Molina A; Alañón, Pardo M T (2005). "Simplex optimization and kinetic determination of nabumetone in pharmaceutical preparations by micellar—stabilized room temperature phosphorescence". Analytica Chimica Acta. 528: 77–82. doi:10.1016/j.aca.2004.10.014.
^Murillo, Pulgarín J A; Alañón, Molina A; Alañón, Pardo M T (2005). "Simplex optimization of the variables affecting the micelle-stabilized room temperature phosphorescence of 6-methoxy-2-naphthylacetic acid and its kinetic determination in human urine". Analytical Biochemistry. 339 (1): 157–164. doi:10.1016/j.ab.2005.01.012. PMID15766723.
^Pulgarín; Murillo, Jose A; Aurelia Alañón, Molina; Robles Ignacio, Sánchez-Ferrer (2005). "Simple and rapid determination of the active metabolite of nabumetone in biological fluids by heavy atom-induced room temperature phosphorescence". Analytica Chimica Acta. 554 (1–2): 37–42. doi:10.1016/j.aca.2005.08.040.
^Patel Bhavin, N; Naveen, Sharma; Mallika, Sanyal; Arpana, Prasad; Shrivastav Pranav, S (2008). "High-throughput LC-MS/MS assay for 6-methoxy-2-naphthylacetic acid, an active metabolite of nabumetone in human plasma and its application to bioequivalence study". Biomedical Chromatography. 22 (11): 1213–1224. doi:10.1002/bmc.1047. PMID18651608.
^Wolff, J C; Hawtin, P N; Monté, S; Balogh, M; Jones, T (2001). "The use of particle beam mass spectrometry for the measurement of impurities in a nabumetone drug substance, not easily amenable to atmospheric pressure ionisation techniques". Rapid Communications in Mass Spectrometry. 15 (4): 265–272. Bibcode:2001RCMS...15..265W. doi:10.1002/rcm.214. PMID11223957.
^Sheen, J F; Her, G R (December 2004). "Application of pentafluorophenyl hydrazine derivatives to the analysis of nabumetone and testosterone in human plasma by liquid chromatography-atmospheric pressure chemical ionization-tandem mass spectrometry". Analytical and Bioanalytical Chemistry. 380 (7–8): 891–7. doi:10.1007/s00216-004-2877-6. PMID15700167.
^Adegoke, A O; Idowu, S O; Olaniyi, A A (2007). "Novel determination of nabumetone, a cox-2 inhibitor precursor via its 4-carboxyl-2,6-dinitrobenzene diazonium (CDNBD) derived AZO dye". African Journal of Medicine and Medical Sciences. 36 (3): 249–257. PMID18390065.